Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

被引：2

作者：

Timmerman, John ^{[1
]}

Lavie, David ^{[2
]}

Johnson, Nathalie A. ^{[3
]}

Avigdor, Abraham ^{[4
]}

Borchmann, Peter ^{[5
]}

Andreadis, Charalambos ^{[6
]}

Bazargan, Ali ^{[7
,8
]}

Gregory, Gareth P. ^{[9
]}

Keane, Colm ^{[10
]}

Tzoran, Inna ^{[11
]}

Vucinic, Vladan ^{[12
]}

Zinzani, Pier Luigi ^{[13
,14
]}

West, Rachel Marceau ^{[15
]}

Pillai, Pallavi ^{[15
]}

Marinello, Patricia ^{[15
]}

Herrera, Alex F. ^{[16
]}

机构：

[1] UCLA, Med Ctr, Los Angeles, CA USA

[2] Hadassah Med Ctr, Jerusalem, Israel

[3] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada

[4] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[5] Univ Hosp Cologne, Cologne, Germany

[6] UCSF, San Francisco, CA USA

[7] Univ Melbourne, Melbourne, Vic, Australia

[8] St Vincents Hosp, Fitzroy, Vic, Australia

[9] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Australia

[10] Princess Alexandra Hosp, Brisbane, Qld, Australia

[11] Rambam Hlth Care Campus, Haifa, Israel

[12] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Cell Therapy & Hemostaseo, Leipzig, Germany

[13] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[14] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[15] Merck & Co Inc, Rahway, NJ USA

[16] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song
Quanli Gao
Huilai Zhang
Lei Fan
Jianfeng Zhou
Dehui Zou
Wei Li
Haiyan Yang
Ting Liu
Quanshun Wang
Fangfang Lv
Haiyi Guo
Liudi Yang
Rebecca Elstrom
Jane Huang
William Novotny
Vivian Wei
Jun Zhu
Leukemia, 2020, 34 : 533 - 542
[32] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Elstrom, Rebecca
Huang, Jane
Novotny, William
Wei, Vivian
Zhu, Jun
LEUKEMIA, 2020, 34 (02) : 533 - 542
[33] An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
von Tresckow, Bastian
Morschhauser, Franck
Ribrag, Vincent
Topp, Max S.
Chien, Caly
Seetharam, Shobha
Aquino, Regina
Kotoulek, Sonja
de Boer, Carla J.
Engert, Andreas
CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1843 - 1850
[34] AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Sasse, Stephanie
Brockelmann, Paul Jan
Momotow, Jesko
Plutschow, Annette
Huttmann, Andreas
Basara, Nadezda
Koenecke, Christian
Martin, Sonja
Bentz, Martin
Grosse-Thie, Christina
Thorspecken, Sven
de Wit, Maike
Kobe, Carsten
Dietlein, Markus
v Tresckow, Bastian
Fuchs, Michael
Borchmann, Peter
Engert, Andreas
LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1871 - 1878
[35] Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients
Leung, Abraham C. F.
Kummar, Shivaani
Agarwala, Sanjiv S.
Nemunaitis, John J.
Gonzalez, Rene
Drabick, Joseph J.
Schmidt, Emmett V.
Chartash, Elliot
Xing, Biao
Currie, Graeme
Janssen, Robert
Ribas, Antoni
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
Ribas, Antoni
Milhem, Mohammed M.
Hoimes, Christopher J.
Amin, Asim
Mehmi, Inderjit
Lao, Christopher D.
Conry, Robert Martin
Shaheen, Montaser F.
Jang, Sekwon
Salama, April K. S.
Deva, Sanjeev
Medina, Theresa Michelle
Schmidt, Emmett V.
Leung, Abraham C. F.
Xing, Biao
Janssen, Robert
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] lTumor Microenvironment in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma before and after Anti-PD-1 Therapy
Gusak, Artem A.
Lepik, Kirill V.
Mikhailova, Natalia B.
Kondakova, Elena
Zalaylov, Yuri R.
Popova, Marina O.
Ionova, Tatiana I.
Kulagin, Aleksandr D.
Afanasyev, Boris V.
Baykov, Vadim
BLOOD, 2020, 136
[38] Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study
Yusuf, Rushdia
Jemielita, Thomas
Marinello, Patricia
BLOOD, 2021, 138
[39] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study (vol 22, pg 512, 2021)
Kuruvilla, J.
Ramchandren, R.
Santoro, A.
LANCET ONCOLOGY, 2021, 22 (05): : E184 - E184
[40] Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial
Gurumurthi, Ashwath
Chin, Collin K.
Feng, Lei
Fowler, Nathan H.
Strati, Paolo
Hagemeister, Fredrick B.
Fayad, Luis E.
Westin, Jason R.
Obi, Chizobam
Arafat, Janine
Nair, Ranjit
Steiner, Raphael E.
Neelapu, Sattva S.
Flowers, Christopher R.
Nastoupil, Loretta J.
ECLINICALMEDICINE, 2024, 74

← 1 2 3 4 5 →